Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBE2109 in Endometriosis Associated Pain
NCT02778399Phase 2Completed
- Sponsor
- ObsEva SA
- Start
- Jul 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of linzagolix in endometriosis (6 arms), sponsored by ObsEva SA. Primary endpoint: Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS). Started Jul 2016; status: completed.
02
Drugs
linzagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT02778399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778399.